Neuro & ImmuneRA10
Single or box
Loading product
Loading product
Neuro & Immune · Research material
Package information
For product inquiries and additional information, contact lonestarpeptideco@gmail.com.
Compliance notice: For laboratory research use only. Not for human or veterinary use.
Product information is intended for laboratory, academic and commercial researchers aged 18 or over.
Material profile
A synthetic heptapeptide consisting of the ACTH(4-7) fragment extended at the C-terminus with a Pro-Gly-Pro tripeptide tail. This listing is one vial with a 5 mg fill. A box of 10 is available as an optional package. It is catalogued as a research-grade reference peptide for receptor-binding, electrophysiology and analytical method work. For laboratory research use only. Not for human or veterinary use.
Catalog record
| Product | Semax — 5 mg |
|---|---|
| Catalog SKU | SX5 |
| Compound | Semax |
| Appearance | Lyophilized white powder |
| Fill per vial | 5 mg |
| Storage condition | -20 °C, desiccated, protect from light |
Laboratory handling
Arrives as a sealed lyophilized vial inside an insulated cold-shipped carton. Store at -20 degrees C, desiccated and protected from light; short-chain peptides of this type degrade fastest under combined humidity and UV exposure. Open, aliquot and dispose of the material strictly according to the receiving laboratory's own protocols.
Evidence first
This listing does not currently publish lot-specific analytical results. Request and review the applicable documentation before using the material in laboratory work.
Published literature
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro), an analog of the adrenocorticotropin fragment ACTH(4-10) with a C-terminal Pro-Gly-Pro extension. In rat studies, a single application was reported to increase hippocampal BDNF protein and trkB tyrosine phosphorylation, alongside multi-fold increases in BDNF and trkB mRNA, with researchers examining Semax's association with modulation of the hippocampal BDNF/trkB signaling system. Related rodent work reported parallel changes in NGF and BDNF gene expression across hippocampus, frontal cortex, and retina, and a rat model of cerebral ischemia-reperfusion examined genome-wide transcriptional changes — including suppression of inflammatory gene expression — associated with Semax administration. Semax has not completed human clinical trials and holds no regulatory approval for any use.
Describes what the cited studies examined in the systems noted above — not a claim about outcomes for people. Not medical advice.
Product support
No downloadable certificate is currently attached to this listing. Email lonestarpeptideco@gmail.com if your laboratory requires lot-specific documentation for review.
Use the package selector to review the single-vial and box-of-10 formats, then use Email to inquire if you want to ask about that product.
The catalog storage condition is -20 °C, desiccated, protect from light. Follow the handling information on this page and your laboratory's written procedures.
No. It is presented only as laboratory research material and is not for human or veterinary use, food, drugs, cosmetics, household use, or self-administration.
Catalog navigation
Other catalog records grouped under the same editorial collection.
Product inquiries
Contact Lone Star Peptide Co. for product information and inquiries.
Email to inquireRequired notice
For laboratory research use only. Not for human or veterinary use, food, drugs, cosmetics, household use, or self-administration. Product information is provided for material identification, handling, and analytical documentation; it is not medical advice or a statement of clinical safety or effectiveness.